The Race is on - Final-stage trials of the Pfizer-BioNTech vaccine could begin furnishing data before the end of October 2020 that regulators will need to make a call about whether to authorize it for emergency use. Our Members and Followers were the first to know click and see>> https://twitter.com/TOP10STOCKS
“I believe we have a very good vaccine candidate, but we now need to work together on expanding a supply infrastructure that would make the vaccine available globally, so everyone who wants a vaccine could get a vaccine,” Dr. Sahin said.
Mike McDermott, Pfizer’s global-supply president, said in a separate interview that the company is confident in delivering the 100 million doses it has promised this year.
“Phase one is get your initial doses out to at-risk populations and the uptick will be rather quick…In that first phase, we are very comfortable with the supply that we’ve built, meaning the number of doses we can make we believe will be quite effective for those populations,” Mr. McDermott said, referring to high-risk populations such as health-care workers.
Mr. McDermott said that in the second phase of rolling out the vaccine, aimed at mid-2021, the goal is to have the vaccine in physicians’ offices or local pharmacies around the world.
Dr. Sahin said BioNTech is also talking to other manufacturers to expand production, together with Pfizer. Mr. McDermott said Pfizer could potentially free up space in its own manufacturing network to boost vaccine production, but also said there is an opportunity for other companies to help produce the vaccine.
The chief executive of the German company partnering with Pfizer Inc. PFE -0.84% in its coronavirus vaccine effort said the two are racing to increase production to meet the world’s needs, assuming the shot wins a regulatory green light.
The two companies are now scrambling to scale up their manufacturing capacities, said Ugur Sahin, CEO of BioNTech BNTX 4.05% SE. Both companies said they are confident they will be able to deliver all the doses they have already agreed to provide to governments, including the U.S. and the European Union.
BioNTech and Pfizer are among a handful of companies in advanced stages of testing their vaccine. They committed to supplying over 450 million doses this year and next year, contingent on late-stage trials showing the vaccine to be safe and effective, and governments give the go-ahead for its use.
The U.S. government placed an initial order of 100 million doses, with the option to purchase 500 million additional doses. The EU ordered 200 million doses with an option for another 100 million. The government of Japan ordered 120 million doses, and Britain ordered 30 million.All orders are subject to regulatory approval, and only the price of the U.S. deal—$1.95 billion—has been disclosed so far.
BioNTech, a company founded by Dr. Sahin and his wife Özlem Türeci, earlier this year developed over 20 vaccine candidates based on the novel mRNA technology that seeks to program the body to create a protein that would help it combat the coronavirus.
In March, the company teamed up with Pfizer, building on an earlier partnership to jointly develop an mRNA-based influenza vaccine. In July, the companies began the late-stage trial of the candidate that it deemed most promising.
BioNTech’s partnered with Shanghai Fosun Pharmaceutical Co. for the Chinese market, Hong Kong and Macau have already ordered 10 million doses.
Source: Wall Street Journal, OxBridge Research, Daily Stock Deals >>> Join in 22 Seconds it's FREE
Important Disclosure: We always have many open positions including $TNXP, $BNTX - we share our views and opinions to inform and entertain you - We make no recommendations, PERIOD! - it's your job to research, consult and seek professional help, before investing a dime - we make bold predictions and we never imitate and parrot other fools - after the fact - bold predictions by nature have great consequences, and we've been wrong and we've been right - for instance we made a whopping 217% on our $BNTX and on $TNXP we are down 15% - so whatever you read on our websites please take it with a gigantic grain of salt - you may choke or Chuckle Your Way To The Bank!
Editor Daily Stock Deals
The timeline - first article in the series
